The Market for Therapies to Treat Benign Prostatic Hyperplasia Will Exceed $1.3 Billion by 2007, Reports Decision Resources, Inc.
WALTHAM, Mass., Jan. 11 /PRNewswire/ -- In 1997, more than 33 million men in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) had moderate or severe benign prostatic hyperplasia (BPH). Population increases and growth in the number of older people will drive this number to nearly 40 million by 2007. Over the past ten years, new drugs that manage BPH symptoms have replaced surgery as the primary treatment for this condition. Two classes of drugs commonly used to treat BPH are alpha-1 antagonists (alpha blockers) and 5- alpha-reductase inhibitors. Sales of drugs to treat BPH in the seven major markets were approximately $900 million in 1997 and will grow to more than $1.3 billion by 2007.
Benign Prostatic Hyperplasia is a new study from Decision Resources, Inc., that provides a comprehensive evaluation of this condition. The report, which is based on in-depth interviews with opinion-leading physicians, contains detailed information on epidemiology, medical practice, and current and emerging therapies. The study also includes an in-depth unmet needs analysis, an evaluation of economic issues, and sales forecasts for therapies to treat BPH in the seven major markets through 2007.
Benign Prostatic Hyperplasia is part of Mosaic, a series of studies on timely topics, focusing on medical indications that are distinguished by major unmet need or significant changes in medical practice. The report is priced at $12,000. For more detailed report information, contact Jean Carbon, Director, Research Publications, 781.487.3737 (telephone), 781.487.3735 (fax), or carbone@dresources.com (e-mail). Decision Resources, Inc., Bay Colony
Corporate Center, 1100 Winter Street, Waltham, MA 02451. In Europe, contact Ms. Vera Bisegna, +32.2.351.1079 (telephone), +32.2.351.2347 (fax), or vbisegna@compuserve.com (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., and employee-owned since 1990, Decision Resources, Inc., has provided strategic information services for more than 25 years, assessing industry trends in the international health care and pharmaceutical industries. Drawing on a closely linked international network of experts, Decision Resources, Inc., offers its clients the most comprehensive analyses of therapy markets available. |
